Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Gyre Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s EBIT?
- Gyre Therapeutics, Inc. (GYRE) reported EBIT of -$14.36M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s EBIT changed year-over-year?
- Gyre Therapeutics, Inc.'s EBIT decreased by 541.2% year-over-year, from -$2.24M to -$14.36M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s EBIT?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s EBIT has grown at a -56.8% compound annual growth rate (CAGR), from -$87.89M to $7.08M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Gyre Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude